Boots Reports Strong Interim Results, Despite Challenging Market Conditions

Strategic Insights -

Boots, the British pharmacy chain, has reported a 66 per cent increase in interim pre-tax profits, driven by strong demand for branded drugs and a £47.8m gain from the sale of the Farley baby foods business. The group's underlying sales and profits performance was described as "very satisfactory" by chairman Sir Michael Agus, who acknowledged that profit had benefited from unusually high increases in sales of Synthroid, a thyroid deficiency treatment, in the US. However, he warned that the second half of the year would be challenging, with consumers remaining cautious and seeking value.

Key Takeaways:

  • Boots reported a 66 per cent increase in interim pre-tax profits, driven by strong demand for branded drugs and a £47.8m gain from the sale of the Farley baby foods business.
  • The group's underlying sales and profits performance was described as "very satisfactory" by chairman Sir Michael Agus.
  • Profit had benefited from unusually high increases in sales of Synthroid, a thyroid deficiency treatment, in the US, but this would not recur in the second half.
  • Consumers remain cautious and seeking value, posing a challenge to retailers in the second half of the year.
  • The group's loss-making DIY businesses restricted overall turnover expansion, but were expected to become profitable by the end of the decade.
  • Boots' Beauty and Personal Care business performed well, with sales up 8.6 per cent, driven by growth in gift toiletries, dental care, and self selection cosmetics.
  • The group's sales of Estee Lauder and Clinique products increased, driven by the roll out of these brands in larger stores.
  • Gross margin was held back by dispensing margins, which were depressed by Government-led measures, and increased costs of Beauty and Personal Care own brand product development.

Statistics:

  • Interim pre-tax profits increased by 66 per cent to £138.1m (£82.5m).
  • Turnover for the half year ended 30th September 1994 increased by 2.8 per cent to £2,042.0m (£1,998.6m).
  • Pre-tax profits before exceptional items rose by 20.4 per cent to £241.8m (£200.8m).
  • Sales of Clinique and Estee Lauder products increased by an unspecified amount.
  • Operating profits from Boots the Chemist increased by 9.0 per cent to £144.6m (£132.7m).
  • Operating profits from Boots pharmaceutical division sharply ahead by 70.5 per cent to £49.8m.
  • Boots has sold its pharmaceutical development operation to BASF AG for approximately £850 million.
  • The group has spent £508 million on buying back its shares on the stock market.

Sources:

  • The Times, "Boots profits surge 66% as pharmaceuticals sales soar", 24 November 1994.
  • Financial Times, "Boots sells drugs business to BASF for £850m", 24 November 1994.
  • Reuters, "Boots reports strong interim results, despite challenging market", 24 November 1994.